Newsletter

6 June 2024

BTN - 2024 - Sartorius - IF - Infographic - 728x90

ASCO 2024: lorlatinib yields longest ever PFS recorded for ALK+ NSCLC patients

Data from the Phase III CROWN study, evaluating the ALK TKI lorlatinib, has demonstrated the best outcomes ever observed for advanced NSCLC patients.

JOURNAL ARTICLES

Plain language summary of updated results from the CROWN study comparing lorlatinib with crizotinib for advanced NSCLC

This summary discusses the updated results of an ongoing research study called CROWN, which was published in The Lancet Respiratory Medicine in December 2022. In the CROWN study, researchers looked at the effects of two study medicines called lorlatinib and crizotinib.

MORE >>>

Identifying drivers of first-line HR+/HER2− metastatic breast cancer treatment choices

This short communication presents the findings of a survey determining how US cancer specialists decide the first treatment for a certain type of metastatic breast cancer. In a survey of 250 cancer specialists, researchers looked at different factors that might influence decision-making, including patient characteristics, doctors’ opinions about the treatments and other medical and non-medical features. This study also examined the connections between these factors and the cancer specialists’ choice of first treatment.

MORE >>>

COMPANION-002 A clinical trial of investigational drug CTX-009 plus paclitaxel vs paclitaxel in second line advanced BTC

Treatment options for patients with biliary tract cancer are limited. CTX-009, a novel bispecific antibody targeting both DLL4 and VEGF-A, has demonstrated antitumor activity in patients with advanced cancers as both a monotherapy and in combination with chemotherapy. Described here is the design of and rationale for COMPANION-002, a randomized phase II/III study, which will evaluate the safety and efficacy of CTX-009 in combination with paclitaxel versus paclitaxel alone as second-line treatment for patients with advanced biliary tract cancer.

MORE >>>

Discover more journal content

Privacy Policy | Terms & Conditions

This is an email from Taylor & Francis Group. Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited and Taylor & Francis Group, LLC.

Taylor & Francis Group includes, but is not limited to: F1000 Research Ltd; Dove Press Ltd; and the publishing imprints of "Taylor & Francis", "Routledge", and "CRC Press".

We respect your privacy and will not disclose, rent or sell your email address to advertisers without your consent. If you wish to unsubscribe, please click 'Manage preferences' above or write to the Data Privacy Manager, Taylor & Francis Group, 4 Park Square, Milton Park, Abingdon, OX14 4RN, UK. For more information, please review our Privacy Policy.

This email was sent to: